Piper Jaffray upgrades Covidien, Ltd. (NYSE: COV) from Neutral to Overweight. Price target increased from $46 to $60.

Piper analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE